newsfilter
← Latest News
ACCESS Newswire·

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

  • MIRA Pharmaceuticals executed an Amended and Restated Exclusive License Agreement with MIRALOGX LLC to secure worldwide exclusive rights to MIRA-55 & SKNY-1.
  • The agreement grants MIRA global development, commercialization, sublicensing, & intellectual property enforcement rights for both programs.
  • MIRA-55 is an oral investigational drug candidate for chronic inflammatory pain & is not classified as a controlled substance by the DEA.
  • SKNY-1 is an oral investigational candidate for obesity & addiction-related disorders designed to modulate metabolic pathways & reward behaviors.
  • The amendment consolidates MIRA's intellectual property portfolio & establishes a unified global rights structure across its core pipeline.
  • MIRA now controls global rights for its entire pipeline including Ketamir-2, MIRA-55, & SKNY-1.
  • Ketamir-2 is advancing into Phase 2a trials while MIRA-55 & SKNY-1 are moving toward IND filings.
  • The amendment does not materially modify the previously disclosed core economic terms of the existing license arrangements.
  • Both MIRA-55 & SKNY-1 remain investigational compounds without FDA approval or established safety & efficacy in humans.